Oncology - Gastrointestinal
RCT: Sintilimab plus a bevacizumab biosimilar versus sorafenib in unresectable hepatocellular carcinoma.
22 Jul, 2021 | 10:47h | UTCSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase III trial involving 571 pts with unresectable HCC, the anti-PD-1 mAb sintilimab + the bevacizumab biosimilar IBI305 improved PFS (median 4.6 vs 2.8 months with sorafenib; HR 0.56, P <0.0001) & OS (median NR vs 10.4 months; HR 0.57, P <0.0001), https://t.co/UF43FGdMMy
— NatureRevClinOncol (@NatRevClinOncol) June 22, 2021
AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia.
16 Jul, 2021 | 10:46h | UTC
Commentary on Twitter
Out now in @AGA_CGH: AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia. Had great time working on this with @AasmaShaukatMD & @seth_crockett. Hope it's a useful reference! @AmerGastroAssn
https://t.co/UB5hFMq6hc pic.twitter.com/KwHeKjU2dk— Peter Liang, MD MPH (@petersliang) February 19, 2021
Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.
14 Jul, 2021 | 11:07h | UTCNews release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre
RCT: Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma.
13 Jul, 2021 | 09:20h | UTC
Commentary on Twitter
Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy
— JAMA Surgery (@JAMASurgery) June 29, 2021
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
1 Jul, 2021 | 09:44h | UTC
Commentary on Twitter
Now available in Annals of Oncology, the @myESMO clinical practice guidelines for the diagnosis, treatment and follow-up of anal cancer, a rare disease accounting for less than 1% of all cancers https://t.co/usnFsd00BJ pic.twitter.com/bI0v60j8Ft
— Annals of Oncology (@Annals_Oncology) June 30, 2021
Evidence-based clinical practice guidelines for management of colorectal polyps.
25 Jun, 2021 | 10:11h | UTC
RCT: Reduced-intensity chemotherapy among older and frail patients with advanced gastroesophageal cancer provides an improved patient experience with no significant detriment in cancer control.
20 May, 2021 | 08:18h | UTC
Commentary on Twitter
The GO2 trial tested reduced intensity of chemo for pts w adv gastroesophageal cancer & found reducing intensity led to comparable survival but w improved patient experience, & decision-making can be enhanced using geriatric assessment https://t.co/DtZOXcozo7 #GeriOnc
— JAMA Oncology (@JAMAOnc) May 13, 2021
Randomized trial long-term results confirm the benefits of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer
20 May, 2021 | 08:16h | UTC
Commentaries on Twitter
Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe
— Gil Morgan (@weoncologists) May 14, 2021
Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB
— ASCO Publications (@ASCO_pubs) May 5, 2021
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
19 May, 2021 | 08:40h | UTCScreening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Evidence Report: Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials: US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty – JAMA AND Updated USPSTF Guidelines for Colorectal Cancer Screening: The Earlier the Better – JAMA Surgery AND Colorectal Cancer Screening Starting at Age 45 Years—Ensuring Benefits Are Realized by All – JAMA Network Open AND
Modeling study: Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force – JAMA
Author interview: USPSTF Recommendation: Screening for Colorectal Cancer
JAMA Patient Page: Screening for Colorectal Cancer
Guide to enhanced recovery for cancer patients undergoing surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without hyperthermic intraperitoneal chemotherapy.
19 May, 2021 | 08:23h | UTCRelated Guidelines:
See also: Enhanced Recovery After Surgery (ERAS) Society Guidelines
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors
13 May, 2021 | 05:46h | UTCAn updated review of the treatment landscape for advanced gastrointestinal stromal tumors – Cancer
Case-control study shows an increased risk of colorectal cancer in first degree relatives of patients with colorectal polyps.
10 May, 2021 | 00:50h | UTCCommentaries: Intestinal polyps in close relatives can increase risk of colorectal cancer – Karolinska Institutet AND Relatives’ Colonoscopy Results Could Affect Your Colon Cancer Risk – HealthDay
Commentary on Twitter
After adjusting for family history of colorectal cancer, siblings and children of patients with colorectal polyps were found to be at increased risk of colorectal cancer in this study #BMJResearch https://t.co/E30VDw3PqT
— The BMJ (@bmj_latest) May 9, 2021
Review: Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer
7 May, 2021 | 08:23h | UTCHyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review – JAMA Oncology (free for a limited period)
Cohort study: Sugar-sweetened beverage intake in adulthood and adolescence linked to increased risk of early-onset colorectal cancer among women
7 May, 2021 | 08:22h | UTCCommentaries: Daily intake of two or more sugar-sweetened drinks associated with higher bowel cancer risk – BMJ AND Expert reaction to study looking at sugary drinks intake and incidence of early-onset colorectal cancer among women – Science Media Centre
Review: Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer
30 Apr, 2021 | 08:31h | UTC
M-A: Helicobacter pylori eradication therapy to prevent gastric cancer – H. pylori eradication may reduce the incidence of gastric cancer in healthy individuals in East Asian countries
27 Apr, 2021 | 09:21h | UTCHelicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis (link to abstract – $ for full-text – free article here)
Guide to Enhanced Recovery for Cancer Patients Undergoing Liver Surgery
25 Apr, 2021 | 20:53h | UTCSee also: Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations – World Journal of Surgery AND Enhanced Recovery After Surgery (ERAS) Society Guidelines
Systematic review: Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
23 Apr, 2021 | 08:17h | UTC
RCT: An Enhanced Recovery After Surgery (ERAS) program in laparoscopic distal gastrectomy provided a faster recovery, a shorter postoperative hospitalization length, and lower medical costs without increasing complication and readmission rates
16 Apr, 2021 | 06:16h | UTCRelated: Consensus guidelines for enhanced recovery after gastrectomy – British Journal of Surgery AND Current status of the “enhanced recovery after surgery” program in gastric cancer surgery – Annals of Gastroenterological Surgery
See also: Enhanced Recovery After Surgery (ERAS) Society Guidelines
RCT: Low-dose aspirin safely suppresses the recurrence of colorectal polyps in patients with familial adenomatous polyposis
14 Apr, 2021 | 01:49h | UTCChemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Ishikawa et al – Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a randomised, 2×2 factorial trialhttps://t.co/NJ4b77p591#gitwitter #FAP #crcsm
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 2, 2021
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
14 Apr, 2021 | 01:27h | UTC
RCT: Celecoxib for 3 years added to standard adjuvant therapy does not improve disease-free survival among patients with stage III colon cancer
7 Apr, 2021 | 01:28h | UTCEffect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Celecoxib for Stage III Colon Cancer – JAMA (free for a limited period)
M-A: Similar oncological outcomes with laparoscopic vs. open rectal cancer resections
5 Apr, 2021 | 00:43h | UTC
RCT: Second-line FOLFOX chemotherapy vs. active symptom control for advanced biliary tract cancer
1 Apr, 2021 | 03:21h | UTCCommentary: Treating patients with advanced biliary tract cancers: Changing tactics – Cancer Research UK
RCT: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
1 Apr, 2021 | 03:19h | UTCAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer – New England Journal of Medicine (link to abstract – $ for full-text)